MarketPulse

zugo-cel

2 articles
The Motley FoolThe Motley Fool··Adria Cimino

CRISPR Therapeutics Eyes $223B Autoimmune Market With Gene-Editing Breakthrough

CRISPR Therapeutics leverages FDA-approved gene editing to target a $223B autoimmune disease market, positioning itself as the post-GLP-1 growth opportunity in biotech.
LLYVRTXNVOCRSPclinical trialsgene therapy
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

CRISPR Therapeutics Advances Gene-Editing Platform With First Approved Therapy

CRISPR Therapeutics gains FDA approval for Casgevy, its first gene-editing therapy for rare blood disorders, validating the platform with multiple pipeline candidates in development.
CRSPFDA approvalclinical trials